Filtered By:
Therapy: Incretin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 82 results found since Jan 2013.

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Publication date: Available online 7 January 2020Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas KeltaiSummaryBackgroundCardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researchi...
Source: The Lancet Diabetes and Endocrinology - January 9, 2020 Category: Endocrinology Source Type: research

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
AbstractDiabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. It appears that these agents exert neuroprotective actions that might both reduce infarct size and promote recovery. The present review summarizes the evidence on the potential role of incretin-bas...
Source: Diabetes Therapy - February 6, 2019 Category: Endocrinology Source Type: research

Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with extrapancreatic effects beyond glycemic control. Here we demonstrate unexpected effects of GIP signaling in the vasculature. GIP induces the expression of the proatherogenic cytokine osteopontin (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB. Infusion of GIP increases plasma OPN concentrations in healthy individuals. Plasma endothelin-1 and OPN concentrations are positively correlated in patients with critical limb ischemia. Fasting GIP concentrations are higher in individuals with a history of cardiovascular di...
Source: Diabetes - December 22, 2015 Category: Endocrinology Authors: Berglund, L. M.; Lyssenko, V.; Ladenvall, C.; Kotova, O.; Edsfeldt, A.; Pilgaard, K.; Alkayyali, S.; Brons, C.; Forsblom, C.; Jonsson, A.; Zetterqvist, A. V.; Nitulescu, M.; McDavitt, C. R.; Duner, P.; Stancakova, A.; Kuusisto, J.; Ahlqvist, E.; Lajer, M. Tags: Complications Source Type: research

Update in Cardiovascular Safety of Incretin-Based Therapy in Adults with Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in MACE, CV death, stroke, and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for HF.
Source: Canadian Journal of Diabetes - April 14, 2019 Category: Endocrinology Source Type: research

Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionsThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.RésuméObjectifsLes auteurs de deux grands essais randomisés ont récemment publié leurs conclusions concernant les effets d'un agoniste du récepteur au glucagon-like peptide-1 (A-GLP-1R) (essai HARMONY) et d'un inhibiteur de la dipeptidyl peptidase 4 (DPP-4) (essai CARMELINA) sur les bénéfices cardiovasculaires (CV) chez les patie...
Source: Canadian Journal of Diabetes - June 5, 2019 Category: Endocrinology Source Type: research

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
CONCLUSION: Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.PMID:35446415 | DOI:10.1210/clinem/dgac200
Source: The Journal of Clinical Endocrinology and Metabolism - April 21, 2022 Category: Endocrinology Authors: Tali Cukierman-Yaffe Hertzel C Gerstein Jan Basile M Angelyn Bethel Ernesto G Cardona-Mu ñoz Ignacio Conget Gilles Dagenais Edward Franek Stephanie Hall Nicolae Hancu Petr Jansky Mark Lakshmanan Fernando Lanas Lawrence A Leiter Patricio Lopez-Jaramillo V Source Type: research

At Centennial of Michaelis and Menten, Competing Michaelis‐Menten Steps Explain Effect of GLP‐1 on Blood‐Brain Transfer and Metabolism of Glucose
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - March 29, 2014 Category: Drugs & Pharmacology Authors: Michael Gejl, Jørgen Rungby, Birgitte Brock, Albert Gjedde Tags: Mini‐Review Source Type: research

At the Centennial of Michaelis and Menten, Competing Michaelis–Menten Steps Explain Effect of GLP‐1 on Blood–Brain Transfer and Metabolism of Glucose
Abstract Glucagon‐like peptide‐1 (GLP‐1) is a potent insulinotropic incretin hormone with both pancreatic and extrapancreatic effects. Studies of GLP‐1 reveal significant effects in regions of brain tissue that regulate appetite and satiety. GLP‐1 mimetics are used for the treatment of type 2 diabetes mellitus. GLP‐1 interacts with peripheral functions in which the autonomic nervous system plays an important role, and emerging pre‐clinical findings indicate a potential neuroprotective role of the peptide, for example in models of stroke and in neurodegenerative disorders. A century ago, Leonor Michaelis and M...
Source: Basic and Clinical Pharmacology and Toxicology - April 30, 2014 Category: Drugs & Pharmacology Authors: Michael Gejl, Jørgen Rungby, Birgitte Brock, Albert Gjedde Tags: MiniReview Source Type: research

Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower cardiovascular risk in type‐2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - May 14, 2014 Category: Endocrinology Authors: Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp‐Pedersen, Gunnar Gislason, Lars Køber Tags: ORIGINAL PAPER Source Type: research

Treatment of Acute and Chronic Neurological Disorders Using GLP-1, Exendin-4 and Analogs
Glucagon-like peptide-1 (GLP-1) and related peptides, including exendin-4 and liraglutide, are incretin mimetics that enhance glucose-dependent insulin secretion following food ingestion as a regulator of glucose homeostasis. Exendin-4 and liraglutide are used clinically in the safe and effective treatment of type 2 diabetes to enhance insulin secretion and maintain a euglycemic state. These actions are primarily mediated at the level of the GLP-1 receptor in the pancreas; however, these compounds are known to enter the brain where the GLP-1 receptor also is expressed. Researchers at the NIH have discovered the novel use o...
Source: NIH OTT Licensing Opportunities - April 18, 2012 Category: Research Authors: admin Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury
Diabetes is one of the most important risk factors and comorbidities of ischemic stroke. Endoplasmic reticulum stress (ERS) is considered to be the major injury mechanism of ischemic stroke with diabetes. Studies have found that incretin can inhibit ERS in ischemia-reperfusion injury of the liver and heart. We aimed to explore the effects of GLP-1/GIP double agonist DA3-CH and GLP-1 single agonist liraglutide on ERS and apoptosis in diabetic rats with cerebral ischemia-reperfusion injury.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - September 10, 2020 Category: Nutrition Authors: Bo Bai, DongFang Li, GuoFang Xue, Peng Feng, MeiQin Wang, YuDi Han, YaNan Wang, Christian H ölscher Source Type: research

The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury
Diabetes is one of the most important risk factors and comorbidities of ischemic stroke. Endoplasmic reticulum stress (ERS) is considered to be the major injury mechanism of ischemic stroke with diabetes. Studies have found that incretin can inhibit ERS in ischemia-reperfusion injury of the liver and heart. We aimed to explore the effects of GLP-1/GIP double agonist DA3-CH and GLP-1 single agonist liraglutide on ERS and apoptosis in diabetic rats with cerebral ischemia-reperfusion injury.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - September 11, 2020 Category: Nutrition Authors: Bo Bai, Dongfang Li, Guofang Xue, Peng Feng, Meiqin Wang, Yudi Han, Yanan Wang, Christian H ölscher Source Type: research

Drug treatments to restore vascular function and diabesity.
Abstract Over the last decades, an escalating rate of type 2 diabetes has paralleled an epidemic rise in the prevalence of obesity. Both diabetes and obesity confer an increased risk of cardiovascular comorbidities, including hypertension, coronary artery disease and stroke. Vascular dysfunction, represented by impaired endothelial release of vasodilator substances or defective smooth muscle vasodilator reactivity, is the early stage of the process leading to atherosclerosis and a common finding in patients with diabesity. It is understandable, therefore, that effective treatments for diabesity should restore vasc...
Source: Annales Pharmaceutiques Francaises - January 1, 2013 Category: Drugs & Pharmacology Authors: Cardillo C Tags: Ann Pharm Fr Source Type: research